Remdesivir Reduces Mortality in Elderly Patients Hospitalized With COVID-19

COVID-19 remains a public health risk, especially for adults over the age of 65, a population that is vulnerable to the virus and at higher risk of serious illness and hospitalization. While previous real-world research has evaluated the effectiveness of remdesivir (Veklury) in reducing mortality among vulnerable patient populations such as immunocompromised and cancer patients hospitalized for COVID-19, evidence demonstrating the drug’s impact on older adults has been sparse.

DocWire News spoke with Jason Okulicz, executive director, Global Medical Affairs, Gilead Sciences, about a study that showed remdesivir reduces mortality in elderly patients (65 and older) hospitalized for COVID-19 during Omicron.